RESUMO OBJETIVOS A pandemia da COVID-19 é um problema de saúde pública emergente e que tem repercussão internacional. As alterações inflamatórias fazem parte da fisiopatologia da COVID-19 e isso pode acarretar um maior risco tromboembólico em mulheres que fazem uso de contracepção e terapia hormonal da menopausa. Discutimos os principais aspectos relacionados a esse risco e propomos uma estratégia de seguimento das mulheres acometidas da COVID-19. MÉTODOS Esta revisão narrativa coletou informações de vários artigos publicados desde o início da pandemia do novo coronavírus, no que tange à sua fisiopatologia, estágios da doença e ocorrência de eventos trombóticos, bem como sobre o risco de tromboembolismo venoso em usuárias de contracepção e terapia hormonal da menopausa. RESULTADOS Este artigo consolida alguns parâmetros clínicos sobre o risco de tromboembolismo em usuárias de contracepção e terapia hormonal na menopausa, enfatizando o provável aumento desse risco em mulheres com suspeita ou confirmação do novo coronavírus, e traz uma recomendação de uma conduta mais segura. CONCLUSÃO Nesse cenário, além das fundamentais orientações de medidas preventivas, como o isolamento social e a higiene, é importante que os profissionais que trabalham na atenção à saúde feminina tenham conhecimentos da nova realidade e adotem condutas seguras, especialmente na prescrição de THM e contracepção.

SUMMARY OBJECTIVES The outbreak of coronavirus disease (COVID-19) is a public health emergency of international concern. Inflammatory changes are part of COVID-19 pathophysiology and this might generate a higher thromboembolic risk in patients using combined hormonal contraception and menopausal hormone therapy. We aimed to discuss the main aspects related to this issue and propose management strategies for women affected by COVID-19. METHODS This narrative review collected information from several articles published since the beginning of the outbreak of the new coronavirus disease about the pathophysiology, stage of the disease, the occurrence of thrombotic events, and the risk of thromboembolism in users of contraception and hormonal therapy. RESULTS This article consolidates clinical parameters about the risk of venous thromboembolism in users of contraception and menopausal hormone therapy emphasizing the probable increase of that risk in women with suspected or confirmed COVID-19 and bringing safer recommendations. CONCLUSIONS In this scenario, apart from the fundamental orientations of preventive measures, like social isolation and hygiene, it is important that all female health professionals have knowledge of the new rules and adopt safety measures, especially on the prescription of hormonal therapy and contraception.

INTRODUCTION: Patients with obstructive sleep apnea-hypopnea syndrome (OSAHS) often have associated changes in craniofacial morphology and distribution of body fat, either alone or in combination. AIM: To correlate cephalometric and anthropometric measures with OSAHS severity by using the apnea-hypopnea index (AHI). METHOD: A retrospective cephalometry study of 93 patients with OSAHS was conducted from July 2010 to July 2012. The following measurements were evaluated: body mass index (BMI), neck circumference (NC), waist circumference (WC), hip circumference (HC), the angles formed by the cranial base and the maxilla (SNA) and the mandible (SNB), the difference between SNA and SNB (ANB), the distance from the mandibular plane to the hyoid bone (MP-H), the space between the base of the tongue and the posterior pharyngeal wall (PAS), and the distance between the posterior nasal spine and the tip of the uvula (PNS-P). Means, standard deviations, and Pearson's correlation coefficients were calculated and analyzed. RESULTS: AHI correlated significantly with BMI (r = 0.207, p = 0.047), NC (r = 0.365, p = 0.000), WC (r = 0.337, p = 0.001), PNS-P (r = 0.282, p = 0.006), and MP-H (r = 0.235, p = 0.023). CONCLUSION: Anthropometric measurements (BMI, NC, and WC) and cephalometric measurements (MP-H and PNS-P) can be used as predictors of OSAHS severity.